Obesity, oxidative stress, and fibrosis in chronic kidney disease

Kidney International Supplements

Volumn 4, Issue 1, 2014, Pages 113-117

  Sharma, Kumar ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

adiponectin; AMPK; inflammation; NADPH oxidase; USF1

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

CHRONIC KIDNEY DISEASE; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; MITOCHONDRION; OBESITY; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84908545060     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2014.21     Document Type: Short Survey

References (38)

1. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342-350.
2. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 2008; 582: 74-80.
3. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
4. Tsioufis C, Dimitriadis K, Chatzis D et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-951.
5. Yano Y, Hoshide S, Ishikawa J et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich) 2007; 9: 775-782.
6. Meyvis K, Verrijken A, Wouters K et al. Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. Metabolism 2013; 62: 1570-1576.
7. Zoccali C, Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 2011; 21: 87-91.
8. Forsblom C, Thomas MC, Moran J et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011; 270: 346-355.
9. Spoto B, Mattace-Raso F, Sijbrands E et al. Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 2013; 28 Suppl 4: iv181-iv187.
10. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
11. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010; 391: 1005-1018.
12. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009; 76: 145-148.
13. Ohashi K, Iwatani H, Kihara S et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 1910-1917.
14. Rutkowski JM, Wang ZV, Park AS et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013; 24: 268-282.
15. Jin X, Chen J, Hu Z et al. Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int 2013; 83: 604-614.
16. Cheng CF, Lian WS, Chen SH et al. Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARalphaheme oxygenase-1 signaling pathway. J Cell Physiol 2012; 227: 239-249.
17. Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Rev Endocr Metab Disord 2013; 15: 157-167.
18. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013; 493: 346-355.
19. Decleves AE, Mathew AV, Cunard R et al. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 2011; 22: 1846-1855.
20. Wang S et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 106: 1117-1128 2010.
21. Sedeek M, Zhang M, Liang B et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010; 299: F1348-F1358.
22. Eid AA, Ford BM, Block K et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem 2010; 285: 37503-37512.
23. You YH, Okada S, Ly S et al. Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol 2013; 304: F840-F848.
24. Aoyama T, Paik YH, Watanabe S et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012; 56: 2316-2327.
25. Gray SP, Di Marco E, Okabe J et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013; 127: 1888-1902.
26. Mishra R, Cool BL, Laderoute KR et al. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008; 283: 10461-10469.
27. Sanchez AP, Zhao J, You Y et al. Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol Renal Physiol 2011; 301: F271-F279.
28. Zhu Y, Casado M, Vaulont S et al. Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 2005; 54: 1976-1984.
29. Godel M, Hartleben B, Herbach N et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209.
30. Cina DP, Onay T, Paltoo A et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012; 23: 412-420.
31. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int 2012; 25: 909-917.
32. Eid AA, Ford BM, Bhandary B et al. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 2013; 62: 2935-2947.
33. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 2005; 29(Suppl 1): S5-S9.
34. Barres R, Osler ME, Yan J et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 2009; 10: 189-198.
35. Steinberg GR, O'Neill HM, Dzamko NL et al. Whole body deletion of AMPactivated protein kinase {beta}2 reduces muscle AMPK activity and exercise capacity. J Biol Chem 2010; 285: 37198-37209.
36. Hoogendijk AJ, Pinhancos SS, van der Poll T et al. AMP-activated protein kinase activation by 5-aminoimidazole-4-carbox-amide-1-beta-Dribofuranoside (AICAR) reduces lipoteichoic acid-induced lung inflammation. J Biol Chem 2013; 288: 7047-7052.
37. Ribaric S. Diet and aging. Oxid Med Cell Longev 2012; 2012: 741468.
38. Ghosh S, Khazaei M, Moien-Afshari F et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol 2009; 296: F700-F708.